

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Ronald Breslow, Paul A. Marks, Richard A. Rifkind, and Branko Jursic

Reissue Application of U.S. Patent No.: 5,369,108

Issue Date: November 29, 1994

For: POTENT INDUCERS OF TERMINAL DIFFERENTIATION  
AND METHODS OF USE THEREOF

Date: <u>11/2/01</u>
EXPRESS MAIL LABEL NO. <u>EV 044389584 US</u>

STATUS OF CLAIMS AND SUPPORT FOR CLAIM CHANGES

UNDER 37 C.F.R. §1.173(c)

Box REISSUE

Assistant Commissioner for Patents

Washington, D.C. 20231

Sir:

This paper is being filed in accordance with 37 C.F.R. §1.173(c) to provide the status of all patent claims, and of all added claims in view of the Preliminary Amendment being filed concurrently. In addition, an explanation of the support in the disclosure of the patent for the changes made to the claims as set forth in the Preliminary Amendment, is provided.

### STATUS OF CLAIMS

As of the date of the Preliminary Amendment being filed concurrently herewith, originally issued Claims 1-17 are pending and newly added Claims 18-29 are also pending.

### SUPPORT FOR CLAIM CHANGES

Claim 1 has been amended to recite that  $R_1$  and  $R_2$  of the structure set forth in the claim are the same and are a substituted or unsubstituted thiazoleamino group. Support for this amendment can be found, *inter alia*, in the originally issued claims and at Col. 7, lines 40-52 of the specification.

Claim 2 has been amended to be in independent form and to recite that  $R_2$  is a hydroxylamino group and is different from  $R_3$ -N- $R_4$ . In addition, the definition of  $n$  has been amended to recite that  $n$  is an integer from 5 to about 8. Support for these amendments can be found, *inter alia*, in the originally issued claims, at Col. 2, line 65-Col. 3, line 6, at Col. 6, line 59-Col. 7, line 7 and in Table 1, as Entries 2-5 of Column "CPD".

Claim 3 has been amended to further define the integer  $n$  as 6. Support for this amendment can be found in originally issued Claim 3 and throughout the specification.

Claims 5 and 7 have been amended to correct obvious typographical errors. Support for this amendment can be found, for example, in Table 1, Entries 51-53 and in the art.

Claims 11, 12 and 13 have been amended to depend from Claim 2 rather than Claim 3. In addition, Claim 11 has been amended to designate the pyridine as a gamma pyridine,  $\gamma$ -pyridine, rather than a delta pyridine,  $\delta$ -pyridine. This is an obvious error, as  $\delta$ -pyridine cannot be a substituent. Support for this amendment can be found in the structures at Col. 17, lines 55-62 and Col. 18, lines 25-33.

Claims 18-29 are newly added. These claims have been added to more specifically claim particular compounds set forth in the specification. Claim 18 is directed to the compositions of the structure set forth in the claim, wherein  $n$  is from 5 to about 8. Support for Claim 18 can be found, for example, in Table 1 as Entries 2-5. Claim 19 is directed to a pharmaceutical composition comprising a therapeutically effective amount of a compound having the structure

set forth in the claim wherein n is from 5 to about 8. Support for Claim 19 can be found, for example, in Table 1 as Entries 2-5 and in the specification at Col. 6, lines 28-31.

Newly added independent Claim 20 is directed to the compound set forth as Entry 3 in Table 1. As such, support for newly added Claim 20 can be found in Table 1 and also at Col. 26, lines 50-68. Newly added independent Claim 21 is directed to a pharmaceutical composition comprising a therapeutically effective amount of the compound set forth as Entry 3 in Table 1 and a pharmaceutically acceptable carrier. As such, support for newly added Claim 21 can be found in Table 1, at Col. 6, lines 28-31 and at Col. 26, lines 50-68 of the specification.

Newly added independent Claim 22 is directed a compound of the general formula set forth, for example, at Col. 6, line 60 and up of the specification, wherein R<sub>2</sub> is a hydroxylamino group, n is 6, R<sub>3</sub> is a  $\gamma$ -pyridine group and R<sub>4</sub> is hydrogen. Support for newly added Claim 22 can be found, *inter alia*, in originally issued Claim 11 and in the structures at Col. 17, lines 55-62 and Col. 18, lines 25-33. Newly added independent Claim 23 is directed to a pharmaceutical composition comprising a therapeutically effective amount of the compound described above with regard to Claim 22 and a pharmaceutically acceptable carrier. Support for newly added Claim 23 can be found, *inter alia*, in originally issued Claim 11 and in the structures at Col. 17, lines 55-62 and Col. 18, lines 25-33, and at Col. 6, lines 28-31 of the specification.

Newly added independent Claim 24 is directed to a compound of the general formula set forth, for example, at Col. 6, line 60 and up of the specification, wherein R<sub>2</sub> is a hydroxylamino group, n is 6, R<sub>3</sub> is  $\beta$ -pyridine group and R<sub>4</sub> is hydrogen. Support for newly added Claim 24 can be found, *inter alia*, in originally issued Claim 12. Newly added independent Claim 25 is directed to a pharmaceutical composition comprising a therapeutically effective amount of the compound described above with regard to Claim 24, and a pharmaceutically acceptable carrier. Support for newly added Claim 25 can be found, *inter alia*, in originally issued Claim 12 and at Col. 6, lines 28-31 of the specification.

Newly added independent Claim 26 is directed to a compound of the general formula set forth, for example, at Col. 6, line 60 and up of the specification, wherein R<sub>2</sub> is a hydroxylamino group, n is 6, R<sub>3</sub> is  $\alpha$ -pyridine group and R<sub>4</sub> is hydrogen. Support for newly added Claim 24 can be found, *inter alia*, in originally issued Claim 13. Newly added independent Claim 27 is directed to a pharmaceutical composition comprising a therapeutically effective amount of the

compound described above with regard to Claim 26 and a pharmaceutically acceptable carrier. Support for newly added Claim 27 can be found, *inter alia*, in originally issued Claim 13 and at Col. 6, lines 28-31 of the specification.

Newly added independent Claim 28 is directed to the compound set forth as Entry 19 in Table 1. As such, support for newly added Claim 28 can be found in Table 1. Newly added independent Claim 29 is directed to a pharmaceutical composition comprising a therapeutically effective amount of the compound set forth as Entry 19 in Table 1 and a pharmaceutically acceptable carrier. As such, support for newly added Claim 29 can be found in Table 1 and at Col. 6, lines 28-31 of the specification.

#### CONCLUSION

In view of the above, it is believed that the requirements of 37 C.F.R. § 1.173(c) are fulfilled. Further, it is believed that all pending claims (Claims 1-29) are in condition for allowance, and it is respectfully requested that the application be passed to issue. If the Examiner feels that a telephone conference would expedite prosecution of this case, the Examiner is invited to call the undersigned at (978) 341-0036.

Respectfully submitted,

HAMILTON, BROOK, SMITH & REYNOLDS, P.C.

By Susan M. Abelleira  
Susan M. Abelleira  
Registration No. 42,252  
Telephone (978) 341-0036  
Facsimile (978) 341-0136

Concord, Massachusetts 01742-9133

Dated: November 2, 2001